Occasional Paper 14: Trends in treated problem cannabis use in the seven health board areas outside the Eastern Regional Health Authority, 1998 to 2002. by Long, Jean
On 14 December 2004 the Minister of State at the Department of
Health and Children, Mr Sean Power, announced the publication of
the third European School Survey Project on Alcohol and Other
Drugs (ESPAD).1 The third ESPAD survey was conducted in 35
European countries during 2003 and collected information on
young people’s alcohol and illicit drug use.
The target population was school-going children born in 1987.
Thus, those surveyed were aged either 15 or 16 years at the time of
the survey. As in the earlier ESPAD surveys, the 2003 survey was
conducted with a standardised methodology and a common
questionnaire to provide comparable European data. 
The publication of the results for the 2003 Irish ESPAD survey allows
comparisons with the previous Irish ESPAD surveys conducted in
1999 and 1995. Trends in some of the main indicators of alcohol
and drug use over the last eight years are reported below.
In terms of alcohol consumption in Ireland, there was a drop in reported regular use of alcohol
(consumed alcohol 20 times or more during last 12 months) by students between 1999 (39%) and
2003 (35%) but proportions were still higher than in 1995 (32%) (Table 1). Confidence intervals are
not provided for these estimates and therefore it is not possible to tell if changes are statistically
significant or not. The ESPAD report acknowledges this limitation, stating that in many countries the
necessary software and resources to calculate confidence intervals were not available.
In the 2003 Irish survey more girls (39%) than boys (31%) reported regular use of alcohol. In fact,
Ireland and Greenland are the only two of the 35 ESPAD participating countries in 2003 where girls
ranked higher than boys in terms of regular alcohol use. Girls in Ireland ranked first in the prevalence
of regular alcohol use, followed by girls in Denmark and in Austria (both 36%).
The ESPAD report provides two measures of heavy alcohol use: drunk ten times or more during the last
12 months and ‘binge drinking’ three times or more during the last 30 days, (Table 1). Binge drinking
is defined in the report as ‘having five or more drinks in a row’. There was little change in both
measures in Ireland between 1999 and 2003 but the overall trend from 1995 continues to be upwards.
In terms of regular drunkenness (drunk ten times or more during the last 12 months), Ireland ranked
second after Denmark (34%) in 2003. In the same year, Ireland ranked highest of the 35 ESPAD
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1995 1999 2003
% % %
Consumed alcohol 20 times or more during last 12 months 32 39 35
Drunk 10 times or more during last 12 months 20 27 29
‘Binge drinking’ 3 times or more during last 30 days 23 31 32
Table 1   Changes in the proportion of school-going children (15–16 years) in Ireland consuming
alcohol in the ESPAD surveys of 1995, 1999 and 2003
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countries in terms of the number of school-going
children who engaged in binge drinking three
times or more in the last 30 days.
In terms of drug use in Ireland, there was a notable
increase in lifetime use of any illicit drug between
1999 (32%) and 2003 (40%), up eight per cent,
(Table 2). This increase followed a drop between
1995 and 1999. Ireland ranked joint third after the
Czech Republic (44%) and Switzerland (41%) for
lifetime experience of any illicit drug in 2003. The
average for the 35 ESPAD countries in 2003 was 22
per cent.
The majority of those who have tried any illicit
drug have used cannabis (marijuana or hashish).
The lifetime prevalence rates for cannabis use are
thus similar to those for use of any illicit drug and
reflect the same trend. Lifetime use of inhalants
dropped slightly between 1999 (22%) and 2003
(18%) but remains high. The average for the 35
ESPAD countries in 2003 was 10 per cent. 
The Irish 2003 ESPAD survey was managed by Dr
Mark Morgan, St Patrick’s College, Dublin, and
funded by the Department of Health and Children.
The sampling strategy involved a two-step process.
All secondary schools were divided into three strata
(single-sex secondary, mixed secondary, and
vocational and community schools). In the first
sampling step, schools were selected within each
strata proportionate to the number of schools in
the sampling frame. A total of 120 schools were
selected in this manner. In the second sampling
step, two grade-five classes were randomly
selected from these schools. Out of the 120
selected schools, 108 agreed to participate and,
out of the 216 classes chosen from these schools,
196 participated. Students in these classes who
were born in 1987 were asked to complete a
questionnaire administered by a teacher in the
school. A special room in each school was
provided for this purpose. Data collection was
carried out during April. A total of 2,407 students
participated in the survey. The response rate
(participating students in participating classes) was
96 per cent. No information was available on the
students in non-participating schools or classes. As
indicated above, the desired target population in
the ESPAD survey was students born in 1987. 
However, the ESPAD report notes that in Ireland
grade five accommodates only about 67 per cent
of all students born in 1987. Consequently, the
Irish results cannot be generalised to 1987-born
students in other grades. (Hamish Sinclair)
1. Hibell et al. (2004) The ESPAD Report 2003. Alcohol and
other drug use among students in 35 European countries.
Stockholm: The Swedish Council for Information on
Alcohol and Other Drugs (CAN), Council of Europe, Co-
operation Group to Combat Drug Abuse and Illicit
Trafficking in Drugs (Pompidou Group).
A key performance indicator under the
prevention pillar of the National Drugs Strategy
2001–2008 is to bring drug misuse by school-
going children to below the EU average and,
as a first step, to reduce the level of substance
misuse by school-going children reported to
ESPAD by 15 per cent by 2003 and by 25 per
cent by 2007 (based on 1999 ESPAD levels).
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Ann Liffey moves to new premises
President McAleese officially opened the new Ana
Liffey Drug Project premises at Middle Abbey
Street, Dublin, on Tuesday 19 October 2004. The
new premises was purchased and refurbished on
behalf of the Ana Liffey project following a ten-year
search for a suitable location. Previously, the
project operated out of rented premises in a
number of different locations in Central Dublin.
Ana Liffey has been providing various services to
individuals and families affected by drug misuse
related problems since 1982, having been one of 
the first voluntary organisations to respond to the
problems associated with drug misuse. Current
service provision by Ana Liffey includes counselling,
peer support training programmes, low threshold
contact, a children’s project, adult literacy, an art
group and literacy training. 
President McAleese commended everyone involved
with Ana Liffey throughout the past 22 years and
observed, ‘In the struggle to get this building and
in the quality of its finish there is a strong message
1995 1999 2003
% % %
Lifetime use of any illicit drug* 37 32 40
Lifetime use of cannabis 37 32 39
Lifetime use of inhalants NA 22 18
*includes cannabis, amphetamines, LSD or other hallucinogens, crack, cocaine, heroin and ecstasy
NA = Not Available
Table 2   Changes in the proportion of school-going children (15–16 years) in Ireland using drugs in the
ESPAD surveys of 1995, 1999 and 2003
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that the users of this service matter, their lives,
their futures matter, not just to those who work
with them on the Project but to the wider
community without whose support and funding
this house would not exist.  It is an important
message of social inclusion to those whose lives or
lifestyles so often put them at the margins, on the
outside.’ (Martin Keane)
The Drug Misuse Research Division of the Health
Research Board would like to take this opportunity
to convey best wishes to the Ana Liffey project in
its new premises. 
Ann Liffey moves to new premises (continued)
EMCDDA Annual Report 2004
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The latest facts and figures on drug use across
Europe, by country, were released by the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) on 25 November 2004 in their Annual
Report 2004.1 The report includes information on
the situation in Ireland provided by the Drug
Misuse Research Division (DMRD) of the Health
Research Board, which is the national focal point
for the EMCDDA.
Key topics addressed, and comparisons made, relate
to population and treated drug use figures (opiates,
cocaine, cannabis and ecstasy), as well as
complications and consequences (such as polydrug
use, psychiatric illness, blood-borne viruses, drug-
related deaths). In addition, there is a special focus
on drug policy.
It is important to stress that the EMCDDA Annual
Report 2004 is based on information provided by
appointed focal points throughout the EU in 2003.
It relates mainly to the drug situation in Europe in
2002 or earlier. 
The following points summarise the current
situation in Ireland: 
■ Ireland’s national drugs strategy is considered
very comprehensive when compared to those
of other EU countries. 
■ Ireland is close to the middle of the ‘EU
range’ in relation to cannabis, cocaine and
ecstasy use among the population. 
■ The prevalence of opiate use among the adult
population (15–64 years) was 5.6 per 1,000
in 2001. This rate reflects a mid-point of the
range (2–10 cases per 1,000) for all European
countries.
■ As in other EU countries, new cases of treated
opiate use decreased by 12 per cent in
Ireland, though numbers continue to rise in
counties outside Dublin.
■ Numbers seeking treatment for cannabis and
cocaine use have increased in Ireland and
these trends are similar to those in other EU
countries.
■ Polydrug use is common among treated drug
users in Ireland, a trend apparent in other EU
countries. During 2002, 76 per cent of
treated drug users in Ireland reported
problem use of two or more drugs, 44 per
cent reported problem use of three or more
drugs and 19 per cent reported problem use
of four or more drugs.
■ The incidence of HIV has not fallen in Ireland
as it has in some other countries in Europe,
but it has stabilised. In Ireland, hepatitis C is a
more pressing problem in relation to blood-
borne viruses among injecting drug users.
Between 1992 and 1998, an Irish research
study estimated that the incidence (new
cases) of hepatitis C among injecting drug
users was 66 per 100 person years; this is 30
per cent higher than estimates reported in
other EU countries. 
■ As in other European countries, the total
number of drug-related deaths in Ireland
decreased in 2001, though numbers continue
to rise in counties outside Dublin. 
■ A number of small-scale research studies in
Ireland indicated that cannabis use is
associated with psychiatric illnesses, in
particular, schizophrenia, psychosis and
depression, while opiate and sedative use is
associated with (possible self-medication for)
depression. On the other hand, some studies
have shown that cannabis can induce
psychotic symptoms. There is no published
national policy or strategy in place to deal
with individuals who have both drug
addiction and psychiatric illness. (Jean Long)
1. EMCDDA (2004) Annual Report 2004: the state of the drugs
problem in the European Union and Norway. Luxembourg:
Office for Official Publications of the European
Communities. 
L to R: Brian Melaugh, Director of Ana Liffey Drug Project,
President Mary McAleese  and Dr David Poole,
Chairperson, Board of Directors of Ana Liffey Drug Project
(Photo courtesy of Ana Liffey Drug Project)
Ireland is close to
the middle of the
‘EU range’ in
relation to
cannabis, cocaine
and ecstasy use
among the
population.
4drugnet
IRELAND
In December 2001 the National Advisory
Committee on Drugs (NACD) launched a
Community/Voluntary Sector Research Grant
Scheme to ‘generate innovative, community-based
drugs research’.1 This grant-supported research
aimed to:
■ promote a better understanding of drug-
related issues in communities
■ boost the research capacity of the
community/voluntary sector and,
consequently, their capacity to influence
policy and the planning of services
■ facilitate liaison between
community/voluntary organisations, service
planners and service providers to optimise the
development of needs-based policies and
services
Following a competitive selection process, five
grants were awarded and four organisations
completed their research projects. These were
written up as four separate reports and launched
by Mr Noel Ahern TD, Minister of State for the
National Drugs Strategy on 4 October 2004.
Two of these reports are featured in this issue:
■ Kilbarrack Coast Community Programme: A
prevalence study of drug use by young
people in a mixed suburban area
■ Tallaght Homeless Advice Unit: Heroin – the
mental roof over your head. Links between
homelessness and drug use
The remaining two reports will be covered in
the next issue:
■ Ballymun Youth Action Project:
Benzodiazepines – whose little helper? The
role of benzodiazepines in the development
of substance misuse problems in Ballymun
■ Merchants Quay Ireland: Drug use among
new communities in Ireland. An exploratory
study
A prevalence study of drug use by young
people in a mixed suburban area
This research study was carried out by Dave
Farrington and Alison Connor on behalf of the
Kilbarrack Coast Community Programme (KCCP).2
The main aim of the study was to establish the
prevalence of drug use, including the use of
tobacco and alcohol, among young people aged
10 to 18 in the KCCP catchment area. This area
includes Kilbarrack and parts of Raheny (North East
Dublin) and coincides with the three electoral
divisions, Grange D, Raheny Greendale and Raheny
Foxfield. The area as a whole is described in the
report as being quite ‘settled’, with low to
moderate levels of socio-economic deprivation.
Rather than survey a representative sample of
young people in the KCCP catchment area, the
researchers set out with the intention to survey all,
or as much as possible, of the area’s youth
population. By extrapolating from the 1996 Census
figures, they estimated that the population aged 10
to 18 in the area was 1,292.
The methodology adopted involved surveying all
school-going children with an address in the
catchment area attending the four primary and
two secondary schools in the catchment area. In
addition, two secondary schools in the
surrounding area were included since they were
known to have a large number of students from
the catchment area. A self-completed
questionnaire was administered in the classroom
setting by the researchers. The exact dates on
which the survey was conducted are not given in
the report. A total of 292 questionnaires were
completed, but seven of these were subsequently
discarded due to inconsistent responses. It is not
clear from the report if all selected school children
responded to the questionnaire. The 285 valid
questionnaires represented a shortfall of over
three-quarters from the estimated population of
this age to be surveyed. A number of possible
reasons were given for this, including:
demographic changes since the 1996 Census;
large numbers attending schools in other areas;
absence from school when the survey was
conducted; and early school leaving. This shortfall
in what was intended to be a census of young
people makes it difficult to generalise from the
results, since the final sample was not a random
selection of young people and it is not clear how
representative those who were surveyed are of the
whole youth population of the KCCP catchment
area. Therefore, the results should be interpreted
with caution.
Table 1 presents the results of lifetime (ever used),
last year (recent use) and last month (current use)
use of selected drugs, including alcohol and
tobacco. 
Of the school children surveyed, lifetime use of
tobacco (54.7%) was higher than that of cannabis
(37.2%); however, recent and current use of
cannabis (31.6% and 21.4% respectively) were
almost as high as recent and current tobacco use
(35.0% and 24.7% respectively). This would suggest
that cannabis was now being used or at least tried as
commonly as tobacco in this group of children.
Another interesting finding is that lifetime and last-
year prevalence rates of cocaine use were the same
(6.1%). This would suggest that cocaine use is a
recent phenomenon in this group of children. 
Community groups carry out research
on local drug issues
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Apart from the school survey, the researchers
administered the same questionnaire to 15 young
people living in the KCCP catchment area who had
left school without completing their Leaving
Certificate (defined as early school leavers in this
study). The early school leavers, aged between 16
and 19, were identified with assistance from local
youth projects and other agencies. While the
numbers in the early school leavers survey were
small, an attempt was made to compare their drug
use with that of school-going children aged 16 to
18 (n=74). One notable difference was that over
half of the early school leavers (8/15=53.3%) were
current cocaine users, compared to less than seven
per cent (5/74=6.8%) of school students.
In an effort to check the findings of the survey the
researchers interviewed 30 adults living or working
in the KCCP catchment area. These individuals
were selected on the basis of their professional,
voluntary or personal involvement with the drugs
issue, or with young people in the community.
According to the authors, the views of the majority
of those interviewed were in line with the main
findings of the survey. (Hamish Sinclair)
1. Details of the Community/Voluntary Sector Research Grant
Scheme can be found on the NACD website at
www.nacd.ie
2. Kilbarrack Coast Community Programme (2004) A prevalence
study of drug use by young people in a mixed suburban area.
Dublin: National Advisory Committee on Drugs.
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Heroin – the mental roof over your head:
Links between homelessness and drug use
This research was carried out by Marie Crawley
and Mary Daly on behalf of the Tallaght Homeless
Advice Unit (THAU).1 The main aim of the research
was to explore the issues, policies and practices
faced by homeless heroin users that contributed to
their becoming and remaining homeless. The
methodology adopted involved semi-structured
interviews with 17 users of the Advice Unit and 13
representatives from statutory, voluntary and
community agencies working in Tallaght. This
article will focus on the findings from the
interviews with service users.
The profile of the 17 service users interviewed (8
women and 9 men) revealed a pronounced
experience of social exclusion and social problems.
Eleven were experiencing homelessness at the time
of interview and 15 were on a methadone
maintenance programme. The group of
interviewees had 27 children between them (17
among the women; 10 among the men). Sixteen
(59%) of the children were aged four or under.
The researchers explored whether drug use initially
contributed to homelessness, and whether
homelessness was sustained by continued drug
use. A majority of interviewees stated that their
drug use contributed to their becoming homeless
initially. Over half of this group reported that their
families were unable to cope with their drug use.
Evictions under anti-social behaviour legislation
and relationship breakdown were cited as
additional factors contributing to homelessness.
Most interviewees agreed that their drug use acted
to sustain their experience of homelessness and
created a barrier to moving out of homelessness.
For example, all but one reported being evicted
from hostels and B&Bs because of drug-related
incidents. In addition, interviewees reported that
becoming homeless greatly exacerbated their drug
use. For example, the transition to using heroin
intravenously was strongly associated with moving
into the homeless scene, particularly when
frequenting emergency hostels and sleeping
rough. Repeatedly, interviewees identified the lack
of accommodation for homeless people in Tallaght
as a factor in exacerbating their drug use, as
travelling into the city centre to access emergency
accommodation increased the likelihood of
involvement in the 'drug scene'.  
Table 1   Lifetime, last year and last month use of selected drugs, including alcohol and tobacco, among
surveyed school-going children (10–18 years) living in the KCCP catchment area 
Used in lifetime   Used in last year   Used in last month
(%) (%) (%)
Alcohol 76.1 66.3 51.0
Tobacco 54.7 35.0 24.7
Cannabis 37.2 31.6 21.4
Inhalants 16.5 7.8 3.9
Sedatives 8.3 4.8 2.2
Cocaine 6.1 6.1 2.5
Ecstasy 3.6 2.2 1.1
Amphetamines 2.9 1.5 0.4
Tranquillisers 2.2 1.5 0.7
LSD 1.1 0.7 0.4
Heroin 0.7 0.7 0.4
Crack cocaine 0.4 0.4 0.0
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Experience of homelessness was mixed, with some
interviewees reporting experiences of extreme
social exclusion. For example, all had some
experience of rough sleeping – under trees, in
building sites, on rooftops, railway carriages, shop
doorways, and on church steps. Some reported
having to walk the street during the day due to
policies of daytime exclusion from emergency
hostels or because of movement between different
accommodations from night to night. On the
other hand, some managed to achieve a degree of
stability when staying in the same B&B for more
than three months. With support from some B&B
staff, interviewees stabilised their drug use and
ensured their children attended local schools. 
When settled in B&Bs or in supported/transitional
accommodation with support and structure in
their lives, interviewees reported stability in their
drug use. The biggest threat to this stability was
being moved into emergency hostels where peer
pressure to misuse and deal drugs was prevalent.
Emergency hostels were clearly identified by all as
the primary risk accommodation associated with
chaotic use of drugs. Hostels were classed on a par
with rough sleeping in terms of exposure to drug
dealing and drug misuse. All repeatedly stated that
their drug use escalated in hostels. Most associated
emergency hostels with their most chaotic periods
in terms of drug use. 
Respondents highlighted the consequences of
drug misuse while experiencing homelessness.
Almost a quarter reported the prevalence of
suicidal thoughts; heroin overdose resulting in
hospitalisation was reported by five respondents.
All respondents had experience of intravenous
drug use, with heroin and cocaine the main drugs
being injected. Injecting heroin was associated
with feelings of being out of control around drugs. 
Interviewees reported mixed experiences of their
engagement with drugs and homeless services.
Most homeless services were perceived to show a
lack of respect for clients when drug use was a
factor. Consequently, interviewees did not feel they
could disclose their drug use to homeless services
for fear of further discrimination. On the other
hand, respondents had little criticism of drugs
services except in reference to the high turnover of
addiction counsellors being a barrier to getting
support with their addiction problems. The
majority of respondents did not experience any
attempt at an integrated approach between
homeless and drugs services. 
Although it is difficult to generalise from this local
study to the wider population of homeless drug
users, the study does raise some issues that merit
further attention from policy makers and service
providers. For example, there was unanimous
agreement that accommodation in emergency
hostels is directly associated with an escalation in
chaotic drug use. On the other hand, when
provided with stable and supported
accommodation, some interviewees stabilised their
drug use and ensured their children attended
school. The research also highlighted the lack of an
inter-agency approach towards drugs and
homelessness and a lack of accommodation
provision for homeless people in Tallaght. 
The report contains a number of recommendations
for policy makers and service providers.   One
particularly pertinent recommendation reads:
'There is a need for a strategic local approach
involving all agencies providing a range of options
to facilitate the phased progression of clients out of
drug use and out of homelessness – this needs to
included a range of accommodation options,
including, but not limited to, B&Bs and local
authority housing.’ The challenge now for the local
authority and drug service providers in Tallaght is
to develop an inter-agency approach to the
problems of homelessness and drug misuse at local
level, and to concentrate resources on providing
localised stable accommodation so as to prevent
vulnerable individuals with drug problems being
exposed to the drug scene in the city centre and
surrounding emergency hostels. Such an approach
over time could provide a good practice model
from which other affected areas could draw
inspiration and guidance. (Martin Keane)
1. Tallaght Homeless Advice Unit (2004) Heroin – the mental
roof over your head: links between homelessness and drug
use. Dublin: National Advisory Committee on Drugs.
Heroin – the mental roof over your head (continued)
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Citywide Family Support Network 
report and seminar
The Citywide Family Support Network held a
seminar on 21 October to mark the publication of
their report, Supporting grandparents... supporting
children.1 Phillip Keegan, a member of the
Network’s steering group, opened the seminar,
and Robbie Byrne, chairperson, gave a
presentation on the background to the Network.
The findings and conclusions of the report on the
consultation with a number of carers involved in
family support groups in the greater Dublin area
were presented. The report found that:
■ There was a general sense of helplessness and
isolation among carers
7drugnet
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■ There was a marked variety of experiences
between the various geographic areas
regarding information on and access to
entitlements and services
■ Service provision and practice varied
significantly between the geographic areas
and service providers
■ Legal issues and difficulties, especially in relation
to custody or guardianship, were common
■ The contentious nature of such issues was
compounded by a lack of legal information
and advice at local level
■ Carers often needed practical support and
information but were unaware of where these
were available
■ The support that carers received from others
in their immediate support groups and local
networks was the most important
■ Having an advocate for individuals was seen
as being of immense personal value and
importance
The following are the conclusions and
recommendations of the report:
■ Access to designated, specialised support staff
is vital
■ Local community welfare services must be
open and transparent
■ Representation for carers or their representatives
on the Local Drugs Task Forces is crucial
■ Integration and real partnership between
statutory and community groups at local level
is imperative 
■ Access to high-quality childcare, crèche
places, after-school clubs and activity groups
is essential 
After the presentation of the report, three
grandparent carers presented personal views and
experiences. The main issue arising from their
experiences was the lack of support from statutory
bodies and the lack of clarity regarding entitlements.
The discrepancy between fostering rates and the
Orphan’s Allowance was perceived as unfair.
In the afternoon, workshops were facilitated to
brainstorm problems raised and suggest solutions.
Three main recommendations emerged from this
session:
1. A new, renamed payment system, with easier
access for children in the care of their extended
family.  This is a matter of urgency; immediate
action could be taken to provide information
and support in applying for the Orphan’s
Allowance.
2. Appointment of specific workers to support
families within health board services and at
community level, with particular emphasis on
establishing and resourcing peer-support
groups.
3. A long-term goal was to develop a strategy to
bring about change in the legislation governing
this issue.
(Ena Lynn)
1. Family Support Network (2004) Supporting grandparents...
supporting children: report on the consultation with a number
of carers involved in family support groups in the Greater
Dublin area. Dublin: Citywide Family Support Network.
Citywide Family Support Network (continued)
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Exploring the role of family support
services in drug prevention
On 12 November 2004 the National Advisory
Committee on Drugs (NACD) published a report
on the role of family support services in drug
prevention.1 The report was based on research
carried out by Niall Watters and Duane Byrne of
Unique Perspectives. The aim of the research was
to assess family support services with a view to
establishing the following: 
■ The extent to which current services explicitly
identify drug problems as a target of their
activities;
■ The extent to which family support work may
be judged to play a positive role in the
prevention of drug problems;
■ The potential for expanding the scope of
family support so as to enhance its capacity
with regard to drug prevention.
The method used involved the development of a
database of family support services, a self-
completion questionnaire survey of all services on
the database, and semi-structured interviews with
a small sample of service providers and clients.
Between October 2002 and March 2003, a total of
2,000 services were entered on a database. A
questionnaire was then posted to all 2,000
services. Allowing for changes of postal address,
staff turnover and services no longer in existence,
the final number of services was re-estimated to be
1,750. A total of 461 completed questionnaires
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were returned, representing a response rate of 26
per cent. This low response rate makes it difficult
to generalise from the results since the sample is
unlikely to be representative of all family support
services, a viewed shared by the authors.
Nevertheless, it was felt that the responses
obtained provided a useful platform from which to
explore the role of family support services in drug
prevention. In addition to the questionnaire survey,
17 semi-structured interviews were conducted with
service providers and 14 semi-structured interviews
and one focus group were conducted with service
users. The qualitative information gathered by
these methods makes a useful contribution to the
overall exploratory nature of the study.
Family support services were asked to indicate
whether they perceived drug-related problems to be
a major focus, a minor focus, or not a focus of their
work. Just over one-fifth (21%) reported drug
problems to be a major focus, 40 per cent that they
were a minor focus, and 39 per cent that they were
not a focus of their work.  Seventy per cent of
services with a major focus on drugs estimated that
over 20 per cent of their clients presented with drug
problems. In contrast, 69 per cent of services with a
minor focus on drugs reported that less than 20 per
cent of their clients presented with drug problems;
this rose to 83 per cent in the case of services with
no focus on drugs. The implication of these
responses is that the bulk of support services do not
see themselves as having an explicit role in
responding to drug problems. Interviews with service
providers revealed that services with a major focus
on drugs see drugs as the main contributory factor
to problems clients present with, and services with
no focus on drugs see drug problems becoming
more prevalent among a minority of clients. 
More than half (57%) of the services felt that they
made a positive contribution to drug prevention.
This work may include a focus on reducing risk
factors and strengthening protective factors in the
family, without necessarily focusing on drug-
specific issues. Thirty eight per cent of services
perceived that their service prevented drug
problems recurring in those that had received
treatment. However, where drug use had moved
to a problematic stage, services with a limited
focus on drugs were less positive about their
influence as a medium for drug prevention.
The research also explored the role of family support
services in drug prevention using the role insecurity
framework. This framework is based on the
assumption that clients with drug problems are often
likely to seek support from and come in contact with
non-specialist services, such as social workers,
community-based groups etc., before presenting to
specialist services. When this occurs, non-specialist
services may experience anxiety about role
legitimacy, role adequacy and role support. In the
case of role legitimacy, 65 per cent of services saw
themselves as having a legitimate role in responding
to their clients' drug problems. However, only 40 per
cent felt they had the necessary skills and knowledge
(role adequacy) to respond to these problems. A
majority (64%) of services believed that the level of
support currently available to them was not sufficient
to allow them to work successfully with clients with
drug problems. 
The research looked at how best to enhance the
drug prevention role of family support services.
Suggestions included:
■ New programmes and initiatives, including
new service areas and target groups, for
example first-time and teenage parents in at
risk neighborhoods;
■ Extra resources, including drug-related
information materials, staff, premises and
funding; 
■ Promoting the work of family support services
to those at risk of drug-related problems and
promoting awareness of the risks associated
with drug use;
■ Training for support service staff;
■ Co-ordination and integration of services
toward drug prevention ends;
■ Mainstreaming drug prevention work within
current service structures.
Overall, the authors suggest that family support
services have the potential to play a greater role in
drug prevention. A number of key issues emerged
that warrant further attention if this role is to be
developed. These include: 
■ The introduction of drug prevention to the
professional training of those who work in
family support services; 
■ The role of drug prevention in the services to
be adequately resourced, officially sanctioned
and mainstreamed in policy terms; 
■ Considerable thought and resources are
required to assist the services to develop
appropriate evaluation and monitoring
systems that will allow them to enhance their
role in drug prevention; 
■ Increased and planned co-ordination between
services that deal with families and drug
problems;
■ Enhanced communication between family
support services and the wider society
regarding their role in contributing to drug
prevention. 
(Martin Keane)
1. Watters N and Byrne D (2004) The role of family support
services in drug prevention. Dublin: Stationery Office.
Exploring the role of family support services (continued)
More than half
(57%) of the
services felt that
they made a
positive
contribution to
drug prevention.
9drugnet
IRELAND
The findings presented in this paper1 indicate that
the number of people treated for cannabis use
outside Dublin and counties Kildare and Wicklow
trebled between 1998 and 2002, from 14.7 to
50.5 per 100,000 of the 15–64-year-old
population. In total, 70 per cent of those who
sought treatment for problem cannabis use
reported that it was their main problem drug. 
The increase in the numbers treated may be
explained by a combination of factors, such as an
increase in access to treatment centres, an increase
in the number of centres reporting cases to the
National Drug Treatment Reporting System, or a
possible increase in cannabis supply.
Regional trends show that the rate of new cases
(per 100,000 of the 15–64-year-old population)
presenting for treatment, when compared with the
period 1996–2000 (Fig. 1), tended to be higher
between 1998 and 2002 (Fig. 2), with demand for
treatment spreading to the south-east and north-
west of the country. The increase in the rates
treated between these two periods was greatest in
Carlow (62.9, up from 27.6), Sligo (39.0, up from
16.3), followed by Cork (53.4, up from 34.5) and
Kerry (29.2, up from 10.6).
There was a small decrease in the proportion of
cannabis cases that reported using other drugs as
well as cannabis, from 83 per cent in 1998 to 78
per cent in 2002, although polydrug use remained
a common practice. Ecstasy and alcohol were the
most common second drugs used in conjunction
with cannabis as a main problem drug. 
When the socio-demographic characteristics of
treated cannabis users were examined, important
patterns were identified. Between 1998 and 2002,
the number of new cannabis cases under 18 years
old who received treatment increased from 21 per
cent to 31 per cent, and an increasing number
reported that they were still attending school.
Those aged 17 years or under require different
approaches to treatment.  Although the vast
majority of treated cases were male, there was a
small rise in the number of females attending for
treatment with cannabis as their main problem
drug. (Jean Long)
1. Kelleher T, Long J, Kelly F and Sinclair H (2004) Trends in
treated problem cannabis use in the seven health board areas
outside the Eastern Regional Health Authority, 1998 to 2002.
Occasional Paper 14. Dublin: Health Research Board.  
Occasional Paper 14: Trends in treated problem
cannabis use in the seven health board areas outside the
Eastern Regional Health Authority, 1998 to 2002
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Figure 1  1996–2000 Figure 2  1998–2002
Between 1998
and 2002, the
number of new
cannabis cases
under 18 years
old who received
treatment
increased from
21 per cent to 31
per cent.
Average annual incidence of treatment for cannabis as a main problem drug among persons aged 15 to 64 years
by county of residence per 100,000 population (Central Statistics Office 2003) based on returns to the NDTRS,
1996 to 2002
Less than 10 cases per 100,000
population
10-19.9 cases per 100,000 population 
20-49.9 cases per 100,000 population 
50 cases or more per 100,000
population 
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In 2002, the National Advisory Committee on
Drugs commissioned a team at Dublin City
University to explore the management of
individuals with a combination of mental illness
and substance misuse in Ireland. The definition of
dual diagnosis used for this study was ‘the co-
existence of both mental health and substance
misuse problems for an individual’. Two distinct
groups of service providers treat patients with
combinations of such illnesses, the mental health
services and the addiction services.
The report1 was launched on 1 November 2004. In
order to review the management of dual diagnosis
in Ireland, the researchers:
■ Reviewed relevant national and international
literature to identify the most appropriate
methods of assessment, treatment and
management of such illnesses. 
■ Organised an open forum in one geographical
area with a representative group of
stakeholders (n=58/60, 97%). This included
service users, mental health and addiction
service providers, social service providers and
representatives from the police. Participants
considered the findings of the literature review
in the context of their personal experience of
dual diagnosis. The proceedings were
documented and the transcriptions were
analysed and themes were identified.
■ Carried out a national postal survey in order
to provide a national overview of service
provision for dual diagnosis in Ireland. This
survey also ascertained attitudes towards and
opinions about the place of dual diagnosis in
Irish health services. A stratified sample by
occupation and county of employment was
selected. The participants were managers,
clinicians and other service providers
(n=141/191, 74%). The questionnaire
consisted of 35 questions. 
■ Completed face-to-face semi-structured
interviews with 10 per cent of the
respondents to the national survey (n=14) to
explore the key findings. The responses were
taped and transcribed. 
A number of key themes were identified during
the open forum:
■ Respondents found it difficult to
conceptualise, define and assess the severity
of dual diagnosis;
■ Policy development to date did not recognise
dual diagnosis; 
■ The general practitioner was the first point of
contact and the main service provider;
■ Clients experienced stigmatisation,
discrimination and marginalisation at
addiction and mental health services;
■ Services were not always client centred,
sometimes normal practices overrode client
needs;
■ It was difficult for clients to access services; 
■ Few formal structures and protocols were
provided to guide staff;
■ Application of evidence-based practice varied;
■ There was inadequate communication and
liaison between services;
■ Clients were lost in the gaps between the
addiction and mental health services; 
■ Professionals working in addiction services
were educated separately to those working in
mental health services;
■ Differences in the professional cultures of the
two services led to conflicting beliefs and
practices;
■ There were difficulties in respecting
professional care and treatment provided by
the ‘other’ service;
■ Multi-disciplinary approaches were more
effective than single-discipline approaches;  
■ A variety of service models exist, mainly serial,
sometimes parallel and occasionally
integrated. 
These themes were used to develop the
questionnaire for the national survey. 
The main findings of the national survey were:  
Over one-fifth of service providers reported that
policies to address dual diagnosis were available in
their area. The examples cited by respondents
indicated that these policies address aspects of
dual diagnosis rather than dual diagnosis itself.
None of the plans or service reviews submitted to
the researchers addressed the specific issue of dual
diagnosis. Over two-fifths of service providers
reported that formal and informal structures
existed in their area, with more in addiction
services (56%) than in mental health services
(33%). In theory, one-fifth of respondents thought
refusing treatment to people with dual diagnosis
was justified. In practice, a large proportion of
providers in the addiction (58%) and the mental
health (43%) services reported that exclusion
criteria applied to people with a dual diagnosis.
The source of referral differed between the mental
health services and addiction services. The mental
health services accepted referral through general
practitioners only, while the addiction services
accepted referrals from a wide variety of sources
(including self-referrals). 
In relation to assessment, 93 per cent of
respondents thought routine screening should be
in place and 66 per cent reported that they always
assessed clients for dual diagnosis. Sixty-three per
Policy, planning and services to address
dual diagnosis in Ireland
A variety of
service models
exist, mainly
serial,
sometimes
parallel and
occasionally
integrated.
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cent of respondents agreed with the statement,
‘Clinical staff in my service are adequately trained
to assess dual illnesses’, and 71 per cent strongly
agreed with the statement, ‘Our service identifies
clients with dual diagnosis’. According to the
service providers, dual diagnosis is recorded for 37
per cent of cases. No respondent used a validated
tool to assess dual diagnosis. 
There is some ambiguity in relation to the
recognition and treatment of dual diagnosis,
evidenced by the lack of service structures and the
extent of exclusion criteria. For example, 92 per
cent of respondents from mental health services
reported that they treat people with substance
misuse problems, yet 43 per cent of respondents
reported exclusion criteria applied to people with a
dual diagnosis. Seventy-one per cent of
respondents reported that they do not follow
recommended models of treatment and 39 per
cent of respondents agreed with the statement,
‘Clinical staff in my service are adequately trained
to treat dual diagnosis’.
Overall, the responses indicated that there was
little systematic co-ordination of care for people
with dual diagnosis evident in any health board
area; only 18 per cent of services offered a specific
service. There were at least three models of service
provision in operation: a parallel model (52%), an
integrated model (29%) and a serial model (16%),
although three-quarters of survey respondents
agreed with the statement, ‘A fully integrated
service is the best way to help people with dual
diagnosis’. 
Respondents reported that 76 per cent of services
had formal communication links with other
services, while 54 per cent had informal
communication links. Respondents were generally
content with the level of communication between
addiction and mental health services, though this
was strongly influenced by those who had
responsibilities across both service areas. According
to the authors, a higher proportion of respondents
from the addiction services disagreed with the
statement ‘Communication between addiction and
mental health services is adequate to treat dual
diagnosis’ than the proportion of their
counterparts in the mental health services,
(p<0.03).2
There was consensus throughout the study that
GPs should be involved in the management of
people with dual diagnosis.
It is clear that a published national strategy is
required to deal with individuals who have both
drug addiction and psychiatric illness. In practice,
there is a need to:
■ Formalise referral procedures between the
mental health services and the addiction
services; 
■ Reconsider exclusion criteria;
■ Use valid assessment tools; 
■ Develop and expand the small number of
evidence-based dual diagnosis services in
existence;
■ Provide appropriate treatment for psychiatric
illness and problem drug use, regardless of
the treatment provider or setting. 
In order to improve responses, further research is
required to estimate the prevalence of dual
diagnosis, to ascertain the needs of persons with
dual diagnosis and define the role of primary care
professionals in the management of these
combined conditions. (Jean Long)
1. MacGabhann L, Scheele A, Dunne T, Gallagher P,
MacNeela P, Moore G and Philbin M (2004) Mental health
and addiction services and the management of dual diagnosis
in Ireland. Dublin: Stationery Office.
2. A p-value is a probability value which measures the
likelihood that the observed association occurred due to
chance.  Probability is measured on a scale of zero to one.
By convention, a value of p <0.05 is considered statistically
significant (for health-related studies).  A value of p <0.05
means that there was a less than one in twenty probability
that the observed association occurred by chance alone.  
Dual diagnosis in Ireland (continued)
Update on drug-related infectious diseases
The National Disease Surveillance Centre (NDSC)
monitors a number of infectious diseases in
Ireland, of which three can be transmitted through
injecting drug use. The organisation published its
annual report for 2003 in November 2004.1
The data on HIV in Ireland in 2003 were reported
in Drugnet Ireland, Issue 12. There were 547 cases
of viral hepatitis type B notified in 2003; this is an
increase of 19 per cent on the 2002 figure. Up to
2004, hepatitis C was not a notifiable disease but
could be reported as ‘viral hepatitis, type
unspecified’. There were 85 cases of viral hepatitis,
type unspecified, notified in 2003, of which 91 per
cent were identified as hepatitis C. There is little
information available on risk groups or sources of
infection, therefore the reported incidence of
hepatitis B and hepatitis C among injecting drug
users in 2003 cannot be determined. Information
on risk factors is required in order to plan
interventions to control and manage these
infections. Furthermore, the incidence of hepatitis
B and hepatitis C among injecting drug users is
one of the key indicators on drug use monitored
by the European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA). At present it is not
possible for Ireland to comply with this key
indicator. (Jean Long)
1. National Disease Surveillance Centre (2004) Annual Report
2003. Dublin: NDSC. 
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Health promotion, the role of the media, service
provision and the need for research to inform
policy have been identified as the important issues
in formulating a region-wide policy on hepatitis C.
These were the key findings of the report of a
consultation process involving service users, service
planners and a wide range of health and social
care professionals launched in December 2004. 
In addition, peer support, education and training,
liaison between services facilitated by liaison nurses
and key workers, making services more accessible
and exploring the role of psychological and
complementary approaches to treatment were
identified as important actions to address 
these issues.
The report was based on the findings of a
consultation event held in June 2004 and
organised to assess the health and social care
requirements for those with or at risk of acquiring
hepatitis C.1 The method used in the consultative
process was ‘open space technology’.  ‘Open space'
is a qualitative methodology used to enable a large
and diverse group of people to explore complicated
issues in a limited time by presenting participants
with central themes. Organic and self-organising, the
participants set a detailed agenda and subsequently
facilitate qualitative discussion at impromptu
workshops. The contents of the discussions are
simultaneously documented. The central themes,
presented in the invitation to this event, were: ‘What
are the significant issues in formulating a region-wide
policy on hepatitis C’; and ‘What are the optimum
approaches to these issues?’
Over 70 people attended the event; among them
were service planners, health and social care
professionals and service users. With respect to the
first of the central themes, the participants
identified the issues they would like on the agenda
on the morning of the event. 
The participants identified 16 significant issues and
a workshop was organised for each issue. A small
group discussion took place on each topic and a
workshop facilitator recorded the issues raised
during the discussion. These data were
subsequently analysed using qualitative methods. 
Four common themes emerged from the 16
workshops:
■ Health promotion
There is need to develop a set of consistent
messages on modes of transmission, pathways to
treatment and success of treatment, with such
messages delivered through a variety of media. 
■ Role of the media
Another need was to ensure that the mass media
provides accurate information to the general public
and high-risk groups. It was suggested that the
media use an approach that allays fears and
reduces the stigma associated with the infection. 
■ Service provision
It was noted that access to and availability of
services to prevent or treat hepatitis C should not
be associated with mode of transmission. There is
a need for equivalence of care between several
groups, for example, those who acquired their
infection through blood products versus injecting
drug users; those who live in Dublin versus outside
Dublin; and those in prison versus those in the
community. The information about, criteria for and
pathways to treatment should be transparent and
easily accessed. Expansion of nursing and
psychology services to support those testing
positive for hepatitis C is required. 
■ Research, policy and planning
In general, the participants emphasised the
importance of an extended surveillance system to
ascertain the extent of the problem but stressed
that such a system must protect the identity of the
individual. Participants also wanted research to
develop best-practice protocols (including medical
and complementary therapies) to manage this
infection. 
In the afternoon session, the process was repeated
to explore optimum approaches to the themes
identified in the morning. Eight actions were
identified and a workshop was organised to deal
with each action. A number of common themes
emerged from the second set of workshops:
■ Peer support and prevention 
The importance of using peer groups in planning
and developing prevention, harm reduction and
treatment interventions was stressed. Peer-group
insight and experience was considered very useful
in ensuring that new approaches would be
appropriate. It was also suggested that indicators
would be developed to monitor and evaluate
prevention and harm reduction interventions. 
■ Education and training
The actions suggested were in line with the health
promotion actions identified in the morning
session. 
■ Liaison, key workers, co-ordination and
collaboration
A number of suggestions were made, including
appointment of key workers (such as liaison
nurses); development of transparent
communication policies and procedures;
improvement in access to services through multi-
agency collaboration; and introduction of a core
monitoring group to ensure client-centred services.  
■ Accessing services
Developments to make services more accessible
and user-friendly were identified as a priority. 
Exploring responses to hepatitis C
through an open space event
Expansion of
nursing and
psychology
services to
support those
testing positive
for hepatitis C is
required.
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■ Psychological and complementary therapies
Respondents thought that psychological support
and complementary therapies, in conjunction with
medication, would be very beneficial to a client’s
quality of life. 
The event represented an ongoing collaboration
between two groups – the Hepatitis C Scientific
Advisory Subgroup of the Blood Borne Virus Forum
(a group of health and social care professionals
with an interest in hepatitis C and related issues)
and the Eastern Regional Health Authority (ERHA).
At the launch of the report in December 2004, the
ERHA presented its response to the findings and its
plans for the future. It was indicated that a group
convened to formulate a regional policy on
hepatitis C intends to audit the health services
available to those with hepatitis C and to actively
provide information on service availability and
identify models of best practice both nationally
and internationally.
In Ireland there are two major groups of people
infected with hepatitis C: those who were infected
by receiving blood products and those infected by
using drugs, with the latter group accounting for
the majority of new infections. Hepatitis C is an
emerging public health problem and is likely to be
a considerable economic burden on the health
services in the future. (Taru Burstall, Olivia Carr,
Caroline Corr, Walter Cullen, Jean Flanagan, Michele
Tait and Jean Long)
1. Hepatitis C Scientific Advisory Subgroup of the Blood Borne
Virus Forum and the Eastern Regional Health Authority
(2004) Hepatitis C in the Eastern Regional Health Authority:
results of a multi-agency consultation event. Dublin:
Unpublished.
A copy of this report may be obtained from
Michele Tait, Eastern Regional Health Authority
(Tel: 01-6201750 or Email: mtait@erha.ie).
Exploring responses to hepatitis C (continued)
Health and social status of women
injecting drug users
Between May 1997 and October 1998, Merchants
Quay Ireland evaluated the activities and outcomes
of the work programme at its Health Promotion
Unit. One of the findings of the research was that
new female injectors were significantly more likely
to suffer from physical and mental health problems
than their male counterparts.1 This was surprising,
as new female injectors had shorter injecting
careers than new male injectors. Based on this
finding, Merchants Quay Ireland designed a study
to examine the health status of female drug users
attending the Unit.2 The study employed a mix of
quantitative and qualitative methods and was
funded by the Health Research Board. The research
was conducted over an eight-week period and
commenced in November 2001. 
The researchers conducted a focus group to
ascertain female drug users’ interest in the research
project and to assist the design of appropriate data
collection tools. They administered a health
information form to establish the participants’
socio-demographic details, drug-using history
including drug-taking practices, sexual-risk
behaviours, current health problems, and prior use
of health services. Following completion of the
health information interview, participants took part
in semi-structured interviews. The data collected
during the semi-structured interviews provided
insight into each woman’s perception of her health
status and her past experience of primary care
services. Each client had a detailed medical
assessment, which included a medical, surgical and
gynaecological history. Details of current
medication were documented. A physical
examination and laboratory tests were completed.
Seventeen clients completed the health
information form and participated in the semi-
structured interviews. Fifteen clients had a medical
assessment, though two did not request any
laboratory tests. Eleven women returned for follow-
up interventions.  
At the time of the study the main findings were:
■ Of the 17 women interviewed, the majority
were under 30 years of age (14/17), homeless
(9/17) and had child-care responsibilities
(11/17). Almost half of the women (8/17)
reported that they their partner was an
injecting drug user. 
■ Heroin was the primary drug of choice for all
17 participants. Over three-quarters were
polydrug users. All 17 had injected illicit
drugs and nine were currently injecting. Of
those currently injecting, six had experienced
one or more problem at an injection site.
Thirteen were currently taking prescribed
methadone. Excluding methadone, eight
participants were taking other prescribed
medications, mainly antidepressants and
sleeping tablets. 
■ Over two-fifths (7) of the participants
reported that their health status was either
bad or very bad. In the three months prior to
the study, 16 women reported psychological
problems; of these, 11 reported anxiety and
14 reported depression. With respect to
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sexual risk factors, three women reported
ever having a sexually transmitted infection. 
■ Of the 16 clients who had a medical
assessment, six reported that they had
asthma, while three had epilepsy. Twelve had
experienced a gynaecological problem. Nine
women were either obese or overweight.
Thirteen clients had been admitted to
hospital one or more times and, of these,
three were admitted as a result of a suicide
attempt. In the three months prior to the
study, over three-quarters (13/17) had
contact with a medical service provider. The
most frequent sources of medical consultation
were general practitioner, drug worker and
accident and emergency services. 
■ Of the 17 women who participated in the
interview, 11 had received at least one dose
of the hepatitis B vaccine. Thirteen clients
requested one or more laboratory tests. Of
these, all 13 tested positive for antibodies to
hepatitis C and two tested positive for
antibodies to hepatitis B. 
Overall, the study findings indicate that women
who inject opiates have complex health and social
problems and do utilise health services, though the
services used in each instance may not be the
most appropriate. Polydrug use, depression,
anxiety and hepatitis C were common health
problems for these women, confirming the need
to provide mental health, addiction and infectious
disease interventions at drug treatment centre
level. The young age profile, level of child care
responsibilities and lack of stable housing highlight
the importance of and need for social services
(such as counsellors, family therapists, community
welfare officers and social workers) at all similar
drug treatment centres. (Jean Long)
1. Cox G, O’Shea M and Geoghegan T (1999) Gender
differences in characteristics of drug users presenting to a
Dublin syringe exchange. Irish Journal of Psychological
Medicine, 16(4): 131–135. 
2. Lawless M (2004) Private lives – public issues: an
investigation into the health status of female drug users. In
Pieces of the jigsaw: six reports addressing homelessness and
drug use in Ireland. Dublin: Merchants Quay Ireland.  
Health and social status of women injecting drug users (continued)
The Blanchardstown Community
Policing Forum
A report proposing the establishment of a
community policing forum in the Blanchardstown
Local Drugs Task Force area was launched by Noel
Ahern TD, minister of state with responsibility for
the national drugs strategy, on 22 November 2004.
The proposal to establish a community policing
forum in Blanchardstown coincides with the
ongoing debate on the Garda Síochána Bill 2004.
The Bill, which is currently before the Oireachtas,
proposes the establishment of joint policing
committees at city or county development board
level, made up of representatives of An Garda
Síochána, the local authority, politicians and other
relevant bodies or persons. It is intended that these
committees will facilitate the establishment of local
policing fora to address specific issues in local areas.
Two other community policing fora have already
been established in the context of the national
drugs strategy, one in the Finglas–Cabra task force
area and one in the North Inner City.1 Also, the
Garda Commissioner has established a community
policing forum in Dublin’s ‘A’ Garda district on a
pilot basis.
The purpose of the Blanchardstown report,
Developing integrated policing: the Blanchardstown
Community Policing Forum, was to build upon an
earlier policing seminar held in Blanchardstown in
April 2004. The purpose of that seminar was to
consider the implications of the Garda Síochána Bill
2004 in terms of local policing needs. The seminar
heard submissions from Michael Mc Dowell TD,
Minister for Justice, Equality and Law Reform; Garda
Commissioner Noel Conroy; Denis Bradley, Vice
Chairman of the Northern Ireland Policing Board;
William Soffe of Fingal County Council; Ivana Bacik,
Reid Professor of Criminal Law and Criminology at
Trinity College; and Ann Losty, local resident and
chairperson of the greater Blanchardstown response
to drugs group.
The report reviews a range of studies on the nature
of local crime and policing problems and then
considers other community policing approaches, in
particular those initiated in Northern Ireland
following the recommendations of the Independent
Commission on Policing (the Patten Report), and
developments in the north Dublin inner city.
Following a consideration of the provisions of the
Garda Síochána Bill and the policing objectives as
set out in the national drugs strategy 2001–2008,
the report makes a number of recommendations
with regard to the structure and process of a local
community policing forum.
The report highlights an issue that arose during the
policing seminar relating to community concerns as
to the precise status and future role of the policing
fora which are already in existence throughout the
city or which are in the process of being developed,
as in Blanchardstown. The status of policing fora
established prior to the enactment of the legislation 
Overall, the study
findings indicate
that women who
inject opiates
have complex
health and social
problems and do
utilise health
services, though
the services used
in each instance
may not be the
most appropriate.
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remains unclear. In order to ensure that such
lingering doubts are not permitted to undermine
ongoing attempts to develop community policing
fora, the report recommends that this matter be
clarified by the Minister for Justice, Equality and
Law Reform.
The day after the report launch, in response to a
parliamentary question on the progress made to
date in establishing community policing fora,
Minister McDowell stated: ‘The establishment of
community policing fora, in general, needs to be
delivered in the context of an appropriate policy
framework for what will be relatively new
partnership structures involving the gardaí, local
authorities and local communities to deal with a
range of issues of mutual concern. Such a
framework will ensure that community policing fora
are developed in an appropriate, consistent and
properly planned manner. Work is well under way
on the development of such a policy framework.’2
(Johnny Connolly) 
1. Drugnet Ireland, Issue 8, June 2003.
2. Dáil Debates. Written Answers. 23 November 2004, Vol.
593 No. 1, Col. 370.
A copy of this report, written by Johnny Connolly
of the Drug Misuse Research Division, can be
obtained from the Blanchardstown Local Drugs
Task Force, or downloaded from the National
Document Centre on Drug Use website at
www.hrb.ie/ndc 
The Blanchardstown Community Policing Forum (continued)
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Analysis of trends in drug law
enforcement
The Garda Síochána Annual Report 2003 was
published in late 2004.1 The report includes a
specific chapter on drug offences (Misuse of Drugs
Act 1977) (MDA). This details information such as
the number of drug offences in which proceedings
were taken by police division and drug type,
particulars of drugs seized, the number, age and
gender of persons charged, and the nature of the
offence.
Although the numbers of drug seizures in any given
period can be affected by such factors as law
enforcement resources, law enforcement strategies
and priorities, and by the vulnerability of traffickers
to law enforcement activities, seizure numbers are
considered as indirect indicators of the supply and
availability of drugs. As the quantities of drugs seized
can vary significantly from year to year, with a few
very large seizures in one year distorting the overall
picture, the number of separate seizures is generally
regarded as a more useful indicator. Figure 1 shows
drug seizure trends between 1995 and 2003. 
Following a 39 per cent drop in the total number
of drug seizures between 2001 and 2002,2 total
seizures in 2003 increased from 5,603 to 6,377.
This increase came about largely as a result of a
slight increase in cannabis and ecstasy seizures and
a 32 per cent increase in cocaine seizures. 
Cannabis seizures normally make up the bulk of all
drug seizures. However, when we focus on drugs
other than cannabis (Figure 1 inset), we can see,
for example, the steady growth in cocaine seizures,
with most other drugs remaining relatively stable
or declining. Ecstasy seizures rose slightly in 2003,
following a sharp decline since 2000.
A key performance indicator in the national drugs
strategy 2001–2008 is to increase the volume of
opiates and all other drugs seized by 25 per cent
by the end of 2004 and by 50 per cent by the end
of 2008, using seizures in 2000 as a base. It is
apparent from media reports and parliamentary
debates on this subject that volume here is being
calculated in terms of the street value of the total
quantity of drugs seized in a given year. When
volume is assessed in this way, the total value of
seizures has increased from €31 million in 2000 to
€121 million in 2003.3
L to R: Joe Doyle, Coordinator of Blanchardstown Local
Drug Task Force, Noel Ahern, TD, Minister of State with
special responsibility for drugs strategy, Phillip Keegan,
Chairperson of Blanchardstown Local Drug Task Force,
and Johnny Connolly, author of the report
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However, if we use the more reliable indicator of
the number of separate seizures as an indicator of
performance, we can see that the total number of
drug seizures has declined by 17 per cent since
2000 (Table 1). Although the overall trend is
Analysis of trends in drug law enforcement (continued)
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Source: Annual reports of An Garda Síochána, 1995–2003 
Figure 1   Drug seizure trends 1995–2003
downward, the number of heroin seizures has
increased by 10 per cent and the number of
cocaine seizures has increased by 175 per cent
over the same time period.
The total number
of drug offences
where criminal
proceedings
commenced
decreased by just
over 10 per cent
in 2003.
1995 1996 1997 1998 1999 2000 2001 2002 2003
Heroin 209 664 599 884 767 598 802 714 660
Cocaine 42 93 157 151 213 206 300 429 566
Ecstasy 571 405 347 466 1064 1864 1485 1027 1083
Amphetamines 89 217 475 680 467 169 162 243 211
Cannabis 3205 3449 4102 4513 4538 4641 6233 3024 3705
Other 62 416 502 336 269 228 187 166 152
Total seizures 4178 5244 6182 7030 7318 7706 9169 5603 6377
Source: Annual reports of An Garda Síochána 1995–2003
Table 1   Recorded drug seizures 1995–2003
Figure 2   Recorded drug offences where criminal proceedings commenced, by drug type, 1995–2003
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Figure 2 shows trends in prosecutions by drug type
between 1995 and 2003. Cannabis-related
prosecutions made up 58 per cent of the total in
2003, a reduction on the 2002 figure of 65 per
cent. However, cocaine-related prosecutions
accounted for 9 per cent of the total number of
prosecutions in 2003, up from 6 per cent in 2002.
Cannabis, heroin, ecstasy and amphetamine-
related prosecutions all declined during 2003.
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The total number of drug offences where criminal
proceedings commenced decreased by just over
10 per cent in 2003.4 However, a larger proportion
of these (25%) were for drug dealing (Section 15,
MDA) than in the previous year (19%). In 2003,
67 per cent of the offences where criminal
proceedings commenced were for simple
possession (Section 3, MDA).  In 2002, 76 per cent
of offences were for possession.
The annual reports of An Garda Síochána are the
main source of information about crime in Ireland.
However, a number of concerns have been raised
in relation to their reliability. The Expert Group on
Crime Statistics, established to consider such
issues, submitted a number of recommendations
to the Minister for Justice, Equality and Law Reform
in July 2004.5 A minority report of the Expert
Group concluded that a lack of clarity regarding
the collation of information relating to crimes
reported to and recorded by An Garda Síochána
meant that the Group was unable to reach
conclusions ‘about the quality, reliability and
accuracy of Garda data’.6 (Johnny Connolly)
1. An Garda Síochána (2004) Annual report 2003. Dublin:
Stationery Office.
2. See Drugnet Ireland, Issue 10, March 2004.
3. Michael Mc Dowell TD, Minister for Justice, Equality and
Law Reform, Dáil Debates, written answer, 8 December
2004 Vol. 594 No.4.
4. An Garda Síochána (2003) p. 79.
5. Expert Group on Crime Statistics (2004) Report. Dublin:
Department of Justice, Equality and Law Reform.
6. Expert Group on Crime Statistics (2004a) Minority Report.
Dublin: Department of Justice, Equality and Law Reform.    
Analysis of trends in drug law enforcement (continued)
New EU Drugs Strategy to add value to
National Drugs Strategy
The European Union has adopted a new drugs
strategy for the period 2005-2012. This new
Strategy is intended to ‘add value’ to national drugs
strategies as member states use it as a framework for
considering how their national drugs strategies
impact on the drugs strategies of other member
states, the ways in which national drugs strategies
can be mutually supportive, and the contribution
their national drugs strategies can make to
achieving the objectives of the EU Drugs Strategy. 
Improved co-ordination will be the key to adding
value. The Strategy recommends measures to
strengthen the co-ordinating roles of the Council’s
Horizontal Working Party on Drugs (HDG) and the
National Drug Co-ordinators. An official of the
Department of Community, Rural and Gaeltacht
Affairs is Ireland’s designated National Drug Co-
Ordinator.
The new EU Drugs Strategy focuses on two policy
fields, supply reduction and demand reduction,
and two cross-cutting themes, international co-
operation, and research, information and
evaluation.  In the area of supply reduction, the EU
aims to ensure a high level of security for the
general public by taking action against drugs
production, cross-border trafficking in drugs and
diversion of precursors, and by intensifying
preventive action against drug-related crime. In
particular, it will seek to achieve effective co-
operation through developing a joint approach, for
example improving and sharing knowledge at
both EU and national level; intensifying law
enforcement co-operation using existing
instruments and frameworks; harmonising
standards of prosecution practice; enhancing law
enforcement, criminal investigation and forensic
science co-operation between member states that
have common interests and/or face the same drug-
related problems; and intensifying member states’
law enforcement efforts directed at non-EU
countries, especially producer countries and
regions along trafficking routes.
In the area of demand reduction the EU aims to
contribute to the attainment of a high level of
health protection, well-being and social cohesion by
complementing member states’ actions in
preventing and reducing drug use, dependence and
drug-related harms to health and society. The
Strategy states that demand reduction measures
should be part of ‘an effective and integrated
comprehensive knowledge-based system including
prevention, early intervention, treatment, harm
reduction, rehabilitation and social reintegration’.
Furthermore, the measures ‘must take into account
the health-related and social problems caused by
the use of illegal psychoactive substances and poly-
drug use in association with legal psychoactive
substances such as tobacco, alcohol and medicines’.
In the field of international co-operation, the
Strategy aims to reduce the production and drugs
supply to Europe and to assist third countries in
reducing the demand for drugs as an integral part
of political and development co-operation.
Strategic priorities include co-ordinated, effective
and more visible action by the EU in international
organisations and fora in order to enhance and
promote a balanced approach to the drugs
problem; special efforts to align the drug policies
of candidate countries, and potential candidate
countries, with those of the EU; and assisting third
countries, particularly drug-producing and transit
countries, to be more effective in both drugs
demand and drugs supply reduction.
In relation to research, information and evaluation,
the Strategy seeks ‘a better understanding of the
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drugs problem and the development of an optimal
response to it through measurable and sustainable
improvement in the knowledge base and knowledge
infrastructure’. Steps to achieve this include making
full use of the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA) and Europol;
identifying priority research topics to be fostered at
EU level; the promotion by member states and the
EU of large-scale exchanges and dissemination of
research results, experiences and good practices;
training of professionals; and consulting public and
private actors. The importance of evaluation and the
overall responsibility of the European Commission in
this regard are confirmed.
The EU Drugs Strategy 2005–2012 was adopted
by the Council of the European Union, comprising
the heads of state and government of the 25
member states, on 17 December 2004 (15074/04
CORDROGUE 77 SAN 187 ENFOPOL 178 RELEX
564). Its adoption was the culmination of eight
months of deliberation, including:
■ Consultation and deliberation on the way
forward in relation to drugs at an EU
conference in Dublin (Report from the
Presidency to the Council on the Main Elements
Discussed at the Dublin Conference – ‘EU
Strategy on Drugs – the Way Forward’ 10/11
May 2004, 8 June 2004, 9595/04
CORDROGUE 36 + REV 1); 
■ Evaluation of the previous EU Drugs Strategy
and Action Plan by the European Commission
(Communication from the Commission to the
Council and the European Parliament on the
Results of the Final Evaluation of the EU Drugs
Strategy and Action Plan on Drugs
(2000–2004), 9 November 2004, (COM
(2004) 707 Final); 
■ Preparation of ‘snapshots’ of the drug
situation and policy measures at the outset
and close of the EU Drugs Strategy – 1999
and 2004 – by the European Monitoring
Centre for Drugs and Drug Addiction
(EMCDDA), in collaboration with Europol. In
addition, the EMCDDA produced 10 thematic
papers on various aspects of the drugs issue.
These papers are available at
www.emcdda.eu.int 
The EU Drugs Strategy 2005-2012 will form the
basis for two consecutive four-year EU Action Plans
on Drugs, to be drawn up by the European
Commission, after consultation with the EMCDDA
and Europol, and a broad group of experts,
professionals and representatives of civil society. In
early 2005 the Commission is due to bring forward
the first Action Plan, covering 2005–2008, for
consultation with the European Parliament and for
endorsement by the Council. (Brigid Pike)
The new EU
Drugs Strategy
focuses on two
policy fields,
supply reduction
and demand
reduction, and
two cross-cutting
themes,
international co-
operation, and
research,
information and
evaluation.
New EU Drugs Strategy (continued)
From Drugnet Europe
‘Snapshots’ shed light on EU targets
Cited from Drugnet Europe No. 48,
October–December 2004
The European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) produced a ‘snapshot’ of the drug
situation at the start and close of the EU Drugs Strategy
(1999 and 2004), which showed the following: 
■ Levels of heroin use and injecting appear to
have stabilised following epidemic rises in the
1980s to mid 1990s and less people are
starting these behaviours (EU 15). Generally
there has been a levelling off in the upward
trend in drug use prevalence observed in the
1990s, although levels remain historically
high and specific analyses by country, sub-
group or drug type show both rises and falls.
But there is concern around rising levels of
polydrug use and signs of new problems
linked to the intensive use of cannabis,
cocaine and other stimulants (Target 1). 
■ A small but statistically significant reduction in
drug-related deaths was recorded between
2000 and 2001, possibly due to a stabilisation
in heroin use and interventions directly
targeting risk behaviour. This trend seemed to
continue in 2002, although deaths remained
at historically high levels (Target 2). 
■ An increase in treatment availability was
noted during the snapshot period in most
countries as well as an overall rise in the
number of reported treatment demands. The
report states that there is evidence suggesting
that service provision has not only expanded
(primarily substitution treatment) but also
diversified (Target 3).
‘Snapshots’ is available on the EMCDDA website at
http://snapshot.emcdda.eu.int/
(continued on page 23)
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In brief
In June 2004 the Irish Prison Service (IPS) published its
Health Care Standards, including a standard for the provision of
clinical services for the assessment, treatment and care of
substance misusers. Appendix 6 sets out a methadone treatment
programme based on the European Methadone Guidelines.
www.irishprisons.ie
On 23 September 2004 a report on a Cross Border
Organised Crime Threat Assessment was launched at a
seminar in Belfast attended by senior police officers of An Garda
Síochána and the PSNI. The report explores eight key areas of
criminality, including drugs. One objective of the seminar was to
consider the development of a strategic response to the threat
from cross-border organised crime. www.justice.gov.ie
On 1 October 2004 the Criminal Justice (Joint
Investigation Teams) Act 2004 came into force. Giving
effect to an EU Council Framework Decision, the Act provides for
the setting up of joint investigation teams by EU member states,
including Ireland, for a specific purpose and limited period. The
teams will carry out criminal investigations with a cross-border
dimension, particularly organised criminal activities such as drug
trafficking. www.oireachtas.ie
On 18 October 2004 Youth suicide prevention: an evidence
briefing was launched. Produced on behalf of the UK and
Ireland Public Health Evidence Group, the study identifies key
risk areas in need of attention when future prevention
programmes are designed, including substance misuse, and the
availability of means, such as legal or illegal drugs.
www.publichealth.ie
On 18 October 2004 the Tallaght West Child Development
Initiative (TWCDI) launched a research report, How are our kids?
The profile reveals that exposure to crime and anti-social
behaviour, including drugs and drug use, is common and that
some children’s development is adversely affected by behavioural
difficulties including substance abuse. The report discusses possible
preventative approaches to addressing the difficulties encountered
by the children and their families. email: info@twcdi.com
On 25 October 2004 the European Council of Ministers
adopted a Framework Decision (2004/757/JHA) laying down
minimum provisions on the constituent elements of criminal acts
and penalties in the field of illicit drug trafficking. The Decision
focuses on the most serious types of drug offence and excludes
certain types of behaviour as regards personal consumption as
defined by national law. www.europa.org
On 4-5 November 2004 the European Council agreed the
Hague Programme (13993/04 LIMITE JAI 408). Succeeding the
Tampere Programme, this new 5-year programme aims to
reinforce the EU area of freedom, security and justice by 2010.
The EU Drugs Strategy 2005–2012 will form part of the Hague
Programme. http://europa.eu.int/
On 8 November 2004 a Ministerial Meeting of the
British–Irish Council reviewed the work programme to date
of the Misuse of Drugs Sectoral Group and agreed future
activities. Guernsey will lead discussions on interventions with
young people, including formal and informal education projects.
Scotland will take the lead on children of drug misusing parents,
while Wales offered to lead on discussions on undertaking
confidential enquiries into drug-related deaths.
www.britishirishcouncil.org
On 18 November 2004 a report Prison needle exchange:
lessons from a comprehensive review of international
evidence and experience was launched at MQI on Merchants
Quay in Dublin. Co-authored by Rick Lines, Executive Director of
the Irish Penal Reform Trust (IPRT), and published by the
Montreal-based Canadian HIV/AIDS Legal Network, the report
concludes that the controlled provision of sterile syringes in
prisons, with programmes now operating in over 50 prisons in
six countries, is both safe and effective. www.iprt.ie
In November 2004 the National Economic and Social
Forum (NESF) launched its Fourth Periodic Report, evaluating
follow-up action by government departments on NESF reports
completed during 2001–2003. The report outlines progress in
relation to the report (No 22) on the reintegration of prisoners,
including recommendations relating to treatment for prisoners
experiencing substance or alcohol abuse problems, and to the
report (No 24) on early school leavers, including the prevention
of drug misuse.  www.nesf.ie
On 15 December 2004 the European Parliament called on
the European Council to adopt a new approach to the issue of
controlled drugs, ‘a genuine European policy on fighting drugs’.
See Proposal for a European Parliament Recommendation to the
Council on the European Strategy on Fighting Drugs (2005–2012).
Rapporteur: Giusto Catania. (A6-0067/2004 Final).
www.europa.org
On 1 January 2005 the Health Service Executive (HSE) was
established under the Health Act 2004. Replacing the health
boards, the HSE is responsible for managing the health service
as a single national entity. This structural change will have an
impact on the provision of drug-related services, including
implementation of the 28 actions in the National Drugs Strategy
for which responsibility is wholly or partly assigned to the health
boards. www.healthreform.ie
On 17 January 2005 the report Darkness on the edge of town:
an exploratory study of heroin misuse in Athlone and
Portlaoise was launched. Based on interviews with drug service
providers, service users and families connected with heroin, the
report seeks to establish the prevalence of heroin use in the two
towns, and recommends the provision of community-based and
client-centred services, including outreach services. 
www.cyc-net.org/pdf/Darkness.pdf
In January 2005 the Joint Committee on Arts, Sport,
Tourism, Community, Rural and Gaeltacht Affairs
published its report Volunteers and volunteering in Ireland. The
report calls for new sources of funding for volunteering to be
explored, including the ring-fencing of Criminal Assets Bureau
(CAB) funds for projects related to communities affected by the
abuse of drugs and by organised crime. www.oireachtas.ie
(Compiled by Brigid Pike)
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The National Documentation Centre on Drug Use
(NDC) has recently completed a major
reorganisation of its website and has launched a
new electronic newsletter. The new website is the
culmination of an extensive programme of work
involving the addition of a range of new
information resources and improvements in
navigation and design. 
Visitors to the website will now have easier access
the site’s main resources, in particular the
Electronic Library of drug-related research and
recent news stories. The NDC has also distributed
the first issue of its electronic newsletter, carrying
news stories from the website and other
information. 
Electronic Library:  Quick Search 
Each of the subject headings listed under Keyword
Search is linked to a number of terms from the
NDC thesaurus. When one of these subjects is
selected, the search engine retrieves all records in
the NDC database indexed with these terms. This
simplifies and speeds up the searching process.
News Stories and New Publications
The most recent news stories and alerts to new
publications, with links to the full text where
available, will be posted on the home page so that
visitors to the site will be immediately informed
about recent events in the drugs area when they
log on. There are now over 1,700 separate news
items, alerts to new publications and summaries 
of Oireachtas debates in the NDC website’s news
archive.
The DMRD’s report on the drugs situation in
Ireland (submitted annually to the European
Monitoring Centre on Drugs and Drug Addiction)
is now available on the NDC website in the form
of an electronic book.  Each item in the report’s
table of contents acts as a link to that section of
the report, so that visitors can quickly find
information on the topic that interests them.
Electronic Newsletter
In February the NDC launched its new monthly
electronic newsletter. The newsletter provides
summaries of news stories covered in national and
local press and items of interest in specialist health
and addiction publications and websites.
Subscribers to this new service will receive regular
updates on developments in national and
international drug policy and research. 
To subscribe to the newsletter, please contact
Louise Farragher at lfarragher@hrb.ie
The NDC completed its second full year in
December 2004. Its electronic and print collections
have grown significantly during this period and the
number of researchers availing of these services has
increased continuously.  The NDC’s Electronic
Library is a unique resource in that it  provides
online access to a comprehensive collection of Irish
drug-related research literature.  No other country
has attempted to build a collection of this type.
In addition to this electronic collection, the NDC has
built a sizeable library of drug-related literature
which can be consulted by anyone calling to the
library in person. The NDC is committed to working
in collaboration with the research community to
increase knowledge of drug use and addiction in
Ireland. We welcome requests from groups who
would like to organise a visit to the NDC or receive
a presentation describing our information services in
their own premises. (Brian Galvin)
For further information on NDC resources, contact
the National Documentation Centre on Drug Use,
Health Research Board, Holbrook House, Holles
Street, Dublin 2. Tel: 01 676 1176; Email:
ndc@hrb.ie or visit the website at www.hrb.ie/ndc
The National Documentation Centre on Drug Use
is funded by the Department of Community, Rural
and Gaeltacht Affairs under the National
Development Plan 2000–2006.
NDC launches new website and newsletter
There are now
over 1,700
separate news
items, alerts to
new publications
and summaries
of Oireachtas
debates in the
NDC website’s
news archive.
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Welcome to the tenth EDDRA (Exchange on Drug
Demand Reduction Action) column and the first of
2005. The aim of this column is to inform people
about the EDDRA online database, which exists to
provide information to policy makers and those
working in the drugs area on current demand
reduction action across Europe, and to promote
the role of evaluation in reducing the demand for
drugs. The database is co-ordinated by the
European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA). 
In this issue, we present a summary of nine Irish
projects added to the EDDRA database during 2004.
Additional efforts were made during last year to
identify demand reduction projects outside the
Eastern Regional Health Authority (ERHA) area and to
include them on the database. Inclusion of projects
from outside the ERHA is an attempt to document a
greater spread of activities in Ireland. To this end, we
were able to add five projects from outside the ERHA
area to the seven already on the database. 
Projects on the EDDRA database represent ‘good
practice’ interventionist work in drug demand
reduction in Europe. This means that projects must
be based on a logical theoretical model and must
demonstrate that the aims and objectives, target
group(s), activities and human and material
resources required to carry out the work are
consistent with the overall model. In addition, the
project must include an evaluation component,
meaning that it has been evaluated or an
evaluation is being planned or in progress. The
majority of the Irish interventions on the EDDRA
database have been process evaluated in terms of
the composition of the project, its implementation
and the reaction of the target group(s). 
Seven of the nine Irish projects (Table 1) added to
the database in 2004 belong in the category of
selective drug prevention. Selective prevention
strategies target subgroups of the population that
are deemed to be at risk of substance misuse.
Subgroups can be deemed at risk by virtue of area
of residence (e.g. where substance misuse is an
emerging problem in an area), by membership of a
particular population subgroup (e.g. experiencing
social exclusion) or by age (e.g. young people). Of
the remaining two projects, one delivered medical
assistance to individuals with drug-related problems
and the other involved harm reduction activities.
The EDDRA column
Table 1   Nine projects representing good practice in drug demand reduction action in Ireland added to
the EDDRA database during 2004
Area of intervention Project Primary aim
Selective County Carlow Drugs Initiative Empower the local communities to develop 
prevention (CCDI) their own resources thus enabling them to
play a pro-active role in the development 
of drug prevention responses to drug misuse
County Waterford Community Promote drug prevention through raising 
Based Drugs Initiative (CWCBDI) awareness in local communities affected
by drug misuse
Frontline Community Drugs Provide a co-ordinated and integrated 
Project (Co. Waterford) contact for young people between the
ages of 12 and 21 who are involved in 
drug misuse and experiencing social
exclusion because of their drug use and 
and socio-economic background
Ferrybank Drug Prevention Divert at risk 12–20-year-olds in Ferrybank
Project (Co Waterford) from drug and alcohol misuse
Traveller Specific Drugs Address drug use in the traveller 
Initiative community through working with travellers 
and organisations that support travellers
The Health Advice Café Offer direct access to health services and
(The Gaf) Galway provide health information and advice
to young people
Killinarden Drug Primary Create awareness and understanding of
Prevention Group (KDPPG) drug misuse among children, parents
and the local community of Killinarden
Medically assisted Merchants Quay Ireland Provide methadone detoxification and
treatment Methadone Prescribing Service maintenance for clients with the purpose
of reducing the harmful effects of long-term 
drug use
Harm reduction Outreach Services in the Provide an outreach service to individuals
Drugs/AIDS service in the and communities experiencing drug- related 
Eastern Region problems
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As of 1 February 2005 there were 492 projects on
the EDDRA database from 16 countries plus the
European Commission1 (Table 2). Ireland
contributed 46 (9%) of these projects, placing it in
the top one-third of contributors. Most of the Irish
projects have been submitted since 2001.  
With nearly 500 projects, the EDDRA database is a
valuable resource of quality information on good
project design, good implementation processes
and sound indicators of effectiveness in changing
or modifying the initial problem. (Martin Keane)
1. The European Commission is represented on the EDDRA
database by projects that are primarily funded by the
Commission and operate on a multi-city basis across EU
countries.
More information about the EDDRA database can
be obtained from the EMCDDA website at
www.emcdda.eu.int
Alternatively, you can contact the EDDRA Manager
for Ireland, Mr Martin Keane, at the Drug Misuse
Research Division, Health Research Board,
Holbrook House, Holles Street, Dublin 2. Tel: 01
676 1176 Ext 169 or Email: mkeane@hrb.ie
If you would like to contribute to the knowledge
base of good practice interventions by adding your
own particular project to the database, please
contact the EDDRA Manager for Ireland at the
above address. 
The EDDRA column (continued)
Table 2   Number of projects on the EDDRA
database ranked by country (including the EU
Commission) 
Country Number of projects   
Austria 58
Germany 53
Spain 52
Greece 47
Ireland 46
Netherlands 43
Italy 31
UK 27
Finland 26
Denmark 20
Portugal 19
EU Commission 15
Belgium 14
France 14
Luxembourg 11
Norway 9
Sweden 7
Source: EDDRA database 1 February 2005
No 13: Overdose – a major cause of avoidable
death among young people
The current EU drugs strategy and action plan
specially target drug-related deaths, and the
European Council calls on member states to make
available a range of measures that can reduce
overdose deaths. The 13th policy briefing in the
Drugs in focus series, issued by the EMCDDA in
January 2005, concludes that many deaths from
drug overdose among young people in Europe
could be avoided by increasing the proportion of
drug users in treatment and bringing untreated
users into contact with drug services. Other
practical measures include educating users in
avoiding risks, and in recognising overdoses in
their peers and responding appropriately.
This briefing states that overdose, mostly involving
opiates, is a major cause of deaths among young
people in Europe: more than 8,000 acute drug-
related deaths are reported each year. Most
overdose victims are males aged between 20 and
40 years, in most cases opiate injectors and often
homeless or marginalised. Evidence strongly
suggests that a significant reduction in drug
overdose can only be achieved by implementing a
broad range of interventions targeting different
types of risk behaviour.   
Six policy considerations are outlined in the
briefing’s conclusions:
1. Drug overdose has not yet received adequate
attention as a public health issue.
2. Further improvements in the reporting of drug-
related deaths at population level are required,
especially in those countries where registers
remain poor. Follow-up studies and assessment
of innovative interventions, such as the use of
opiate antagonists, are also needed.
3. Opiates still account for most overdose deaths,
but awareness of the role of other illegal and
legal substances needs to be heightened.
4. That overdose is avoidable must become a
central message and a priority issue for drugs
services.
5. Recent reversals in the long-term upward trend
in overdose deaths in some member states are
likely to reflect increased treatment coverage
and decreased levels of risk taking, especially
injecting.
6. The new member states are in a position to
avoid the increases in drug-related deaths
Drugs in focus – Policy briefings
Projects on the
EDDRA database
represent ‘good
practice’
interventionist
work in drug
demand
reduction in
Europe.
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Drugs in focus – Policy briefings (continued)
previously seen in west European countries if
they invest in comprehensive programmes
informed by the available evidence on effective
practices.
No. 14: Co-morbidity – drug use and mental
disorders
The EMCDDA and the World Health Organization
(WHO) have been collaborating over the last year
to raise awareness of the hidden problem of co-
morbidity in Europe. Between 50 and 90 per cent
of drug users are reported to suffer from
personality disorders and around one-fifth from
more serious psychotic illness. 
This policy briefing from the EMCDDA’s Drugs in
focus series identifies some of the problems of
treating such patients. Because the condition is
notoriously difficult to diagnose, both drug
treatment services and psychiatric teams regularly
fail to spot patients with co-morbidity. Drug
addiction and disruptive behaviour often mask
genuine personality disorders and psychiatric
syndromes are often mistaken for substance-
induced states. According to the briefing,
professionals are often ill-equipped to cope with
co-morbidity, resulting in patients being shuttled
between psychiatric and drug services, which
disrupts their treatment and increases drop-out
rates. Co-ordination between services at all points
in the treatment chain is essential for successful
treatment of co-morbidity and for ensuring a
continuum of care and aftercare. Treatment is
effective if highly structured, integrating multi-
professional teams, and customised via individual
case management.  This is both time consuming
and demanding on human and organisational
resources, but in the end is cost-effective.  
Policy considerations summarised in the briefing
include:
■ Treatment for co-morbidity is effective if
delivered according to evidence-based
practice, planned and managed individually.
■ Co-morbid patients need carefully co-
ordinated and integrated treatment services.
■ Training at all levels of each involved
organisation is necessary to enhance staff
capacity to deal with these patients in a
holistic way.
■ Co-ordinated, integrated and flexible
treatment services, including aftercare, will
reduce staff turnover and be cost-efficient.
(Joan Moore)
A report on co-morbidity in Ireland commissioned
by the National Advisory Committee on Drugs is
reviewed on page 10 of this newsletter.
Drugs in focus is a series of policy briefings
published by the European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA). The
briefings are published three times a year in the
20 official languages of the European Union
plus Norwegian. An electronic version of Drugs
in focus is available from the EMCDDA website
at www.emcdda.eu.int
If you would like to receive a hard copy of the
current or future issues of Drugs in focus, please
contact Mary Dunne, Drug Misuse Research
Division, Health Research Board, Holbrook
House, Holles Street, Dublin 2, Tel: 01 676
1176 Ext 127; Email mdunne@hrb.ie
From Drugnet Europe (continued from page 18)
Experts focus on gender differences among
drug treatment clients
Cited from Linda Montanari, Drugnet Europe No.
48, October–December 2004
Women tend to seek treatment for drug problems
less than men, with a male–female ratio ranging
from 5:1 in Greece to 2:1 in the Czech Republic
(all drugs). This ratio varies according to the
primary substance used, with fewer women than
men seeking treatment for cocaine, cannabis and
opiate use and more doing so for drugs such as
hypnotics or sedatives. The male–female ratio also
varies according to characteristics such as age and
education. For example it was found to be: 
■ lower among very young clients (3.6 men to
1 woman <20 years old);
■ lower among those with high levels of
education (3.1 men to 1 woman);
■ lower among people living with children (1.3
men to 1 woman).
At present, data on treatment demand mainly
relate to outpatient treatment centres, but there
are signs that countries are broadening national
data coverage and improving data quality.
(Brigid Pike)
Drugnet Europe is a newsletter published by
the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA). The
newsletter is published four times a year in
Spanish, German, English, French and
Portuguese. An electronic version of Drugnet
Europe is available from the EMCDDA website
at www.emcdda.eu.int
If you would like to receive a hard copy of the
current or future issues of Drugnet Europe,
please contact Mary Dunne, Drug Misuse
Research Division, Health Research Board,
Holbrook House, Holles Street, Dublin 2. Tel:
01 676 1176 Ext 127; Email mdunne@hrb.ie
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Books
Care of drug users in general practice: a harm
reduction approach
Beaumont B (ed) 2nd Edition, Radcliffe Publishing
2004
ISBN 1 85775 624 X
General practitioners may come in contact with
users of a wide variety of drugs, often at a
relatively early stage in their drug-using career. GPs
who have developed skills to manage problems
related to drug use are in a unique position to
facilitate change.  Yet many GPs feel inadequately
trained to take on this work, and some consider
that managing these patients in general practice is
too challenging.
This book, in a fully revised and updated second
edition, aims to inform GPs and primary care
teams on the issues arising from their increased
responsibility for the health care of drug misusers.
It includes chapters on the historical development
of the GPs role; the assessment, general health
care and counselling of drug users; polydrug use;
care of opiate users; stimulants and party drugs;
safer injecting; drug users with special needs;
families and carers, working with other agencies;
and drugs and the law. The final chapter, on
training and professional development, outlines
some of the ways in which generalist GPs can
acquire skills and competencies in the field of
substance abuse. Contributors have first-hand
knowledge of their subjects, whether as general
practitioners, drug treatment service providers, or
primary care specialists. 
Young refugees and asylum seekers in Greater
London: vulnerability to problematic drug use
Centre for Ethnicity and Health, University of
Central Lancashire Greater London Authority 2004
ISBN 1 85261 647 4
This report is the culmination of an 18-month
project undertaken by the Greater London Alcohol
and Drug Alliance (GLADA) and the University of
Central Lancashire, and funded through the Home
Office Confiscated Assets Fund. It looks at the
experiences of young refugees and asylum seekers
in London and examines the extent to which they
are exposed to risk factors for the development of
drug use. 
The project consisted of four elements: research by
six community organisations, feedback to a
stakeholder group, a literature review and a
mapping exercise.  The opening sections of the
report outline the background, rationale and
methods of the project, and include statistics and
an overview of policy. In Section 4, the 67 young
people interviewed give accounts of their decision
to leave their countries of origin, their journeys to
the UK and their experiences on arrival. Sections 5
to 13 focus on nine policy areas identified in the
literature review: education, health, crime,
employment, housing, previous and current drug
use, family, social networks and environment.
Section 14 presents the conclusions and
recommendations of the young people, the
community organisations and the professionals
involved.  
Management of alcohol and drug problems
Hulse G, White J and Cape G (eds) Oxford
University Press 2002
ISBN 0 19 551331 2 
This book is written for medical and other health
practitioners in training, but is also intended as an
evidence-based reference for health professionals
who are increasingly expected to provide
appropriate information, assessment and treatment
in relation to drug and alcohol problems. The book
introduces the fundamentals of alcohol and drug
misuse as applied to the clinical setting, complete
with assessment, diagnostic and management
strategies and tools. Most of the contributors are
or have been involved in undergraduate drug and
alcohol medical education (largely in Australia or
New Zealand).  
The book is organised in four main parts, covering:
the context for drug use, including historical
aspects and general treatment considerations;
details of drugs used, their pharmacology and
epidemiology and methods of treatment; the
application of knowledge gained from study of
specific populations (such as adolescents, women,
people with co-existing mental health illness); and
a review of specific issues that arise in the clinical
setting, including aspects of safe prescribing and
clinical practice.  Key practice points and
suggested further reading are provided, and case
histories are used to illustrate important clinical
issues.
Journal articles
The following are summaries of a selection of
articles relating to the drugs situation in Ireland
recently published in international journals.
Drug use and drug markets in the context of
political conflict: the case of Northern Ireland
McElrath K
Addiction Research & Theory 2004; 12 (6): 577–590
This article examines drug use and drug markets in
Northern Ireland against the backdrop of the most
recent Irish political conflict. The nature of the
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Northern Ireland political conflict contributed to
low levels of drug use in the 1970s and 1980s. In
1994, the cessation of military operations by the
Irish Republican Army (IRA) and Loyalist
organizations led to the possibility of widespread
political and social change. Use of certain drugs,
namely heroin, appeared to increase from the mid-
1990s, although the effects of political conflict on
drug use are less clear during the post-ceasefire era.
Patterns of alcohol consumption and problems
among the Irish in London: a preliminary
comparison of pub drinkers in London and
Dublin
McCambridge J, Conlon P, Keaney F, Wanigaratne
S and Strang J
Addiction Research & Theory 2004; 12(4): 373–384
Alcohol-related morbidity and mortality rates
among the Irish in England and Wales are higher
than both other ethnic minorities and the general
population. Higher consumption per episode of
drinking is responsible for higher overall mean
consumption levels among the Irish. Patterns of
consumption and problems among the Irish were
investigated in two samples recruited in pubs in
London and Dublin. Mean weekly alcohol
consumption was found to be higher, by
approximately 50 per cent, in the London sample,
with more high-risk drinking a result of more
frequent drinking patterns. Hazardous drinking was
strongly normative among young Irish people in
both London and Dublin. The distinct Irish style of
drinking – greater quantities per episode – and the
English pattern of more frequent drinking combine
to produce elevated risk among the Irish in
London. Irish drinking patterns in general, and the
alcohol-related needs of the young Irish in Britain
in particular, require further study to better
understand the nature of risk and to prevent harm.
Smoking, alcohol and illicit drug use among
young people in a health board region in 1997
and 2002: a comparative study
Flanagan E, Bedford D, O'Farrell A, Browne C and
Howell F
Irish Journal of Medical Science 2004; (8):230–4
The objectives of this study were to document and
compare patterns of licit and illicit drug use among
adolescents in a health board region in 1997 and
2002. Students randomly selected from post-
primary schools in the region, 1,516 in 1997 and
1,426 in 2002, completed a questionnaire,
incorporating items related to smoking, alcohol
and illicit drug use. Lifetime smoking prevalence in
2002 (50.8%) showed a statistically significant
decrease from 1997 (57.1%). There was also a
statistically significant decrease in regular smoking
(30.7% in 1997; 18.2% in 2002). There was no
significant change in regular alcohol consumption
(57.3% in 1997; 53.7% in 2002). However, there
was an increase in binge drinking at weekends and
reports of feeling drunk more than ten times (24%
in1997; 27.2% in 2002). In 2002, 41.2 per cent
had ever taken an illicit drug, a statistically
significant increase from 1997 (34.9%); 15.1 per
cent were regular users, also a statistically
significant increase from 1997 (11.9%). These
findings highlight that, while the misuse of illicit
drugs has increased, smoking has significantly
declined since 1997. However, alcohol continues
to be a major problem in this age group. This
study has implications for the implementation of
services and strategies aimed at reducing smoking,
alcohol and drug use in this population.
A systematic review of the utility of self-report
alcohol screening instruments in the elderly
O'Connell H, Chin AV, Hamilton F, Cunningham C,
Walsh JB, Coakley D and Lawlor BA
International Journal of Geriatric Psychiatry 2004;
19(11):1074–86
Effective screening instruments are needed for the
detection of alcohol use disorders (AUDs) in the
elderly, in view of the significant physical,
psychological and social problems associated with
this phenomenon. This paper provides details on
the different self-report alcohol screening
instruments that have been studied in the elderly,
describing both the instruments themselves and
their effectiveness as screening instruments for
AUDs in different elderly populations. The vast
majority of studies reviewed were carried out in
the United States, and a high proportion of these
were carried out in Veterans Administration
institutions, thus limiting the generalisability of
results. The CAGE was the most widely studied
screening instrument, followed by the MAST or
variations of the MAST, the AUDIT and variations
of the AUDIT, and other screening instruments.
Sensitivity and specificity of these instruments
varied widely, depending on the prevalence of
AUDs in the population being studied, the clinical
characteristics of the population and the type of
AUD being detected. The CAGE performed poorly
in psychiatric populations but a newer instrument,
the AUDIT-5, has had promising results to date. No
studies focused on elderly people with cognitive
impairment, and there is a need for research in this
area. Ease of use, patient acceptability, sensitivity
and specificity must all be considered when
selecting a self-report alcohol screening instrument
for use in the elderly. Furthermore, the prevalence
of AUDs in the population and the clinical
characteristics of that population must also be
taken into account. 
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Development of a community pharmacy-based
model to identify and treat OTC drug abuse/
misuse: a pilot study
Fleming GF, McElnay JC and Hughes CM
Pharmacy World & Science 2004; 26(5): 282–288
The aim of this study was to develop and pilot a
harm-minimisation model for the identification and
treatment by community pharmacists of over-the-
counter (OTC) drug abuse/misuse.  Extensive
consultation was conducted during the
development of the model. This included an
exploratory conference involving an
interdisciplinary group of delegates and detailed
individual consultation with a range of healthcare
practitioners. Consultation with a psychologist
specialising in communication skills allowed
development of the communication aspects of the
model. A comprehensive manual detailing the
model was prepared. The model is designed to be
used by community pharmacists in conjunction
with other healthcare professionals. It focuses on
the abuse/misuse of opioids, laxatives and
antihistamines and can be broadly divided into
three phases, namely: patient identification and
recruitment, treatment/referrals and data
collection/outcome measurement. Client
identification is via record-keeping which is
implemented alongside an information campaign
promoting safe use of OTC medicines. Once
identified, the pharmacist aims to recruit clients
using the developed communication strategies.
Treatment depends on the product and on
whether the problem is misuse or abuse. Several
treatment paths are available, including treatment
according to an agreed protocol and referring to
the GP or community addiction team (CAT). Two
pharmacists were recruited and trained to pilot the
model. Of the clients, 18 were identified as
abusing/misusing OTC products over a one-month
period. The subject of inappropriate OTC use was
raised with 14 of these clients. Some success was
noted in that clients agreed to stop using the
product and/or to try safer alternatives. As
expected, some sales had to be refused, as the
client was unwilling to accept the pharmacist's
intervention.  This study represents the first
reported structured attempt by community
pharmacists in the UK to address the abuse/misuse
of OTC medication. Work is now ongoing to
modify this model in light of the pilot study
findings.
Hepatitis C among drug users: consensus
guidelines on management in general practice
Barry J, Bourke M, Buckley M, Coughlan B,
Crowley D, Cullen W, Dooley S, Keating S, Kelleher
D, Moloney J, Murray F, McCormick PA,
MacMathuna P, O'Connor J, O'Grady J, O'Sullivan
C, O'Sullivan P, Quinn C, Smyth B and Sweeney B
Irish Journal of Medical Science 2004;
173(3):145–50
Hepatitis C (HCV) is a common cause of morbidity
among patients who attend general practitioners
(GPs) in Ireland for methadone maintenance
treatment. The aim of this study was to describe
the development and content of guidelines for the
management of HCV among current or former
opiate users in the Eastern Regional Health
Authority area attending GPs for methadone
treatment. The guidelines were produced in five
stages: identification of key stakeholders;
development of evidence-based draft guidelines;
discussion of content; determination of 'Delphi'-
facilitated consensus and review by a sample of
GPs for whom the guidelines would be intended.
The guidelines contain advice for GPs on all
aspects of care of patients at risk of HCV, including
general and preventative care, care of other blood-
borne and hepatotoxic viruses, and the factors to
be considered and appropriate evaluation prior to
referring a patient for assessment at a hepatology
unit. The study concluded that GPs have an
important role to play in the care of patients at risk
of, or infected with, HCV.
Wound botulism in the UK and Ireland
Brett MM, Hallas G and Mpamugo O
Journal of Medical Microbiology 2004; 53(6):
555–561
There are three main, naturally occurring,
epidemiological types of botulism: food-borne,
intestinal colonisation (infant botulism) and wound
botulism. The neurological signs and symptoms
are the same for all three epidemiological types
and may include respiratory paralysis. Wound
botulism is caused by growth of cells and release
of toxin in vivo, is associated with traumatic
wounds and abscesses and has been reported in
drug users, such as those injecting heroin or
sniffing cocaine. Up to the end of 1999 there were
no confirmed cases of wound botulism in the UK.
Between the beginning of 2000 and the end of
December 2002, there were 33 clinically
diagnosed cases of wound botulism in the UK and
Ireland. All cases had injected heroin into muscle
or by 'skin popping'. The clinical diagnosis was
confirmed by laboratory tests in 20 of these cases.
Eighteen cases were caused by type-A toxin and
two by type-B toxin.
(Joan Moore, Louise Farragher)
Recent publications (continued)
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Upcoming events
April
7 April 2005
Sex and drugs
Venue: London
Organised by /Contact: DrugScope events.
Tel: +44 (0) 20 7928 1211
Email: events@drugscope.org.uk
Information: This course is aimed at drug and
alcohol workers at Tiers 2 and 3. Drug use has had
an undeniable impact on the sexual behaviour of a
range of communities across the UK. The
association between drug use and sex work has
become a particular issue for drug services –
although the links between sex and drugs are by
no means limited to sex workers. All this places
drugs workers in a position where they have to
consider sexual behaviour as part of a substance
misuse assessment. On completion of this course,
participants will have a full understanding of the
ways in which different groups (including, but not
restricted to, sex workers) have incorporated drug
use into their sexual activity, and will be able to
provide effective advice to help clients reduce the
risks they face through these altered practices.
Course fee: £140 + VAT.
14 April 2005 (Evening Seminar: 7.30pm)
Reducing Drug-Related Harms: The Uses of
Ambiguity
Venue: Swift Theatre, Arts Building, TCD
Organised by /Contact: Addiction Research
Centre, Trinity College Dublin
Tel: +353 (0) 1 6083647
Email: clarkef@tcd.ie
Information: The speaker is Dr Craig Reinarman,
Department of Sociology, University of  California,
Santa Cruz.  Dr Reinarman is an American social
scientist who has specialised in the study of
societal definitions of and responses to drug and
alcohol use, both in the United States of America
and internationally.  In this seminar he will discuss
the evolution of harm reduction strategies,
focusing particularly on recent debate concerning
the relative merits of basing such policy change on
explicit moral principles or, alternatively, keeping it
shrouded in political ambiguity.  The respondent
will be Dr. Shane Butler, Addiction Research
Centre, TCD, and the seminar will be chaired by
Dr. Paula Mayock, Children’s Research Centre,
TCD.
28–29 April 2005
Management of Drug Users in Primary Care
Venue: Novotel London West Convention Centre,
Hammersmith, London
Organised by / Contact: RCGP and Healthcare
Events. For more information contact Susie
Valentine.
Tel: +44 (0) 208 541 1399
Email: susie@healthcare-events.co.uk
www.drugs.gov.uk/Events/1103643868/
Drugsbrochure2005.pdf
Information: This is the tenth annual conference
on the subject, and is aimed at a range of
stakeholders including generalists and specialist
GPs, shared care workers, pharmacists, drug users
and joint commissioners.
May
12 May 2005
Employee Drug Testing: Complying with the
Proposed Safety, Health & Welfare at Work Bill
2004
Venue: Butler House, Kilkenny
Organised by / Contact: Caroline Cahill, EAP
Institute, 143 Barrack Street, Waterford.
Tel: +353 (0) 51 855733
Fax: +353 (0) 51 879626
Email: eapinstitute@eircom.net
19–21 May 2005
2nd UK/European Symposium on Addictive
Disorders (UKESAD). To Match or Not to Match:
Enhancing Client Outcomes
Venue: Riverbank Park Plaza, London
Organised by / Contact: The Addiction Recovery
Foundation, FDAP, Priory Healthcare, RAPt and
others.  For more information and a booking form
contact the administration office.
Tel: +44 (0) 20 7233 5333 
Email: info@ukesad.org
www.ukesad.org  [Early bird rates for those
booking before 26 March]
Information: This year's UKESAD, entitled 'To
match or not to match – enhancing client
outcomes', will focus on issues identified by
DA/ATs, providers and practitioners as 'hot topics'
of relevance to the delivery and commissioning of
effective treatment services. Contributors include:
Professor Carlo DiClemente on Cycles of Change
for Professionals; John Friel on Couples
Counselling; Dr Iain Bourne on Handling &
Preventing Violence; Bill Puddicombe on Brief
Interventions; Dr Patrick DeChello and colleagues
on Supervision; Dr Harry Sumnall on Evidence-
based Prevention; Professor Bob Lynn and
colleagues on Outcome-based Purchasing and
Provision; and Cathy Howlett and Alan Rosenbach
on Whole-system Commissioning. This event is
accredited for CPD / training credits: FDAP, ICRC,
CME.
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25–26 May 2005
Planning a Service for Young People: an
Overview
Venue: London
Organised by / Contact: DrugScope events.
Tel: +44 (0) 20 7928 1211
Email: events@drugscope.org.uk
Information: This course is aimed at managers and
commissioners of drug services. Young people need
different kinds of drug services to adults. The
triggers for their drug use are often different to
those that drive adult users, young people are
treated differently under the law, and they respond
to a different kind of worker–client interaction. This
two-day course helps workers develop an
understanding of drug misuse among young people
in the context of youth culture, and an awareness of
the law, in particular in relation to confidentiality
and child protection. Participants learn about the
ten key policy principles governing the delivery of
drug services to young people, discuss practical
approaches to working with them, and develop an
action plan for the development of an effective drug
service that meets their specialised needs. Course
fee: £260 + VAT.
June
23 June 2005
Employee Drug Testing: Complying with the
Proposed Safety, Health & Welfare at Work Bill
2004
Venue: Butler House, Kilkenny
Organised by / Contact: Caroline Cahill, EAP
Institute, 143 Barrack Street, Waterford.
Tel: +353 (0) 51 855733
Fax: +353 (0) 51 879626
Email: eapinstitute@eircom.net
July
4–7 July 2005
18th Annual Australian Winter School on 'Drugs,
Lifestyles & Culture' – Innovation & Evidence
Venue: Carlton Crest Hotel, Brisbane, Australia
Organised by/Contact: Alcohol and Drug
Foundation, Queensland. 
Tel:  +61 (0) 7 3834 0211
www.winterschool.info
Information: The 2005 winter school will address
drugs, lifestyles and culture in the context of the
practical application of research and policy for
those working in service delivery.
7–9 July 2005
8th European Conference on Drugs and
Infections in Prison
Venue: Budapest
Organised by / Contact: Cranstoun Drug
Services, European Network on Drug and
Infections Prevention in Prison (ENDIPP) and
others. Contact: Salma Master, Cranstoun Drug
Services.
Tel: +44 (0) 208 543 8333
Email: mailto:smaster@cranstoun.org.uk
www.drugs.gov.uk/Events/1106068808/BudapestFl
yerENG.pdf
Information: This year's event, ‘Unlocking
Potential – making prisons safe for everyone’, will
cover a range of topics, including: though care
and after care; multi-agency working in practice;
and harm reduction.
(Compiled by Louise Farragher)
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If you would like to have an event included in
this listing in future issues of Drugnet Ireland,
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Misuse Research Division, Health Research
Board, Holbrook House, Holles Street, Dublin 2.
Tel: 01 676 1176 Ext 159 or
Email: lfarragher@hrb.ie
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